Insider Selling: GSK plc (LON:GSK) Insider Sells £1,753,088.09 in Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 120,653 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.29), for a total value of £1,753,088.09 ($2,206,530.01).

GSK Price Performance

LON GSK opened at GBX 1,435 ($18.06) on Friday. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The stock’s fifty day moving average price is GBX 1,367.43 and its 200 day moving average price is GBX 1,454.89. GSK plc has a 1 year low of GBX 1,282.50 ($16.14) and a 1 year high of GBX 1,823.50 ($22.95). The company has a market cap of £58.23 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analyst Weigh In

GSK has been the subject of several analyst reports. Berenberg Bank decreased their price objective on GSK from GBX 1,820 ($22.91) to GBX 1,600 ($20.14) and set a “buy” rating for the company in a report on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($22.73).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.